Myriad Genetics (MYGN) Stock Price, News & Analysis

Company Overview

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities. Myriad’s Prolaris® test evaluates prostate cancer aggressiveness by measuring gene expression levels, while its EndoPredict® assay helps predict the likelihood of breast cancer recurrence. The company also provides pharmacogenomic profiling to identify how patients may respond to certain medications, aiding in more precise drug selection and dosing.

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics has expanded its presence internationally, serving healthcare providers in the United States, Europe, Canada, Australia and select markets in Latin America and Asia. The company operates a network of clinical laboratories and collaborates with academic institutions, biopharmaceutical firms and healthcare systems to advance genomic research and develop novel diagnostic solutions.

Under the leadership of President and Chief Executive Officer Mark C. Capone, Myriad continues to invest in research and development to broaden its test menu and drive innovation in precision medicine. The company’s strategic initiatives include expanding direct-to-physician and direct-to-consumer outreach, enhancing its data analytics capabilities and forging partnerships to integrate genetic insights into routine clinical practice.

Key Stats

• Today's Range: $6.77 to $6.97
• 50-Day Range: $3.84 to $6.91
• 52-Week Range: $3.76 to $29.30
• Volume: 187,298 shs
• Average Volume: 1.71 million shs
• Market Capitalization: $646.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.45
• Consensus Rating: Hold

Myriad Genetics Stock Analysis - MarketRank™

Myriad Genetics scored higher than 71% of companies evaluated by MarketBeat, and ranked 301st out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 4 buy ratings, 9 hold ratings, and 1 sell rating.

Upside Potential

Myriad Genetics has a consensus price target of $12.45, representing about 79.6% upside from its current price of $6.94.

Amount of Analyst Coverage

Myriad Genetics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Myriad Genetics are expected to remain at ($0.30) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Myriad Genetics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Myriad Genetics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Myriad Genetics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.07% of the outstanding shares of Myriad Genetics have been sold short.

Short Interest Ratio / Days to Cover

Myriad Genetics has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Myriad Genetics has recently increased by 10.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Myriad Genetics does not currently pay a dividend.

Dividend Growth

Myriad Genetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

10.07% of the outstanding shares of Myriad Genetics have been sold short.

Short Interest Ratio / Days to Cover

Myriad Genetics has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Myriad Genetics has recently increased by 10.24%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.00

News Sentiment

Myriad Genetics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Myriad Genetics this week, compared to 8 articles on an average week.

MarketBeat Follows

1 people have added Myriad Genetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Myriad Genetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.40% of the stock of Myriad Genetics is held by insiders.

Percentage Held by Institutions

99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MYGN Stock Analysis - Frequently Asked Questions

How have MYGN shares performed this year?

Myriad Genetics' stock was trading at $13.71 at the beginning of the year. Since then, MYGN stock has decreased by 49.4% and is now trading at $6.9360.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. Myriad Genetics's revenue for the quarter was down 33.6% compared to the same quarter last year.
Read the conference call transcript.

Does Myriad Genetics have any subsidiaries?

Myriad Genetics subsidiaries include Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and others.

Who are Myriad Genetics' major shareholders?

Myriad Genetics' top institutional investors include Glenview Capital Management LLC (4.93%), Geode Capital Management LLC (2.41%), Qube Research & Technologies Ltd (2.21%) and Camber Capital Management LP (2.15%). Insiders that own company stock include Paul J Diaz, Richard Bryan Riggsbee, Nicole Lambert, Heinrich Dreismann, Lee Nisley Newcomer, Colleen F Reitan and Daniel K Spiegelman.
View institutional ownership trends.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MYGN
• CIK: 899923
• Web: www.myriad.com
• Phone: (801) 584-3600
• Fax: 801-584-3640
• Employees: 2,700
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Myriad Genetics: $12.45
• High Price Target: $21.00
• Low Price Target: $6.00
• Potential Upside/Downside: +80.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.21
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.30 million
• Net Margins: -47.45%
• Pretax Margin: -50.47%
• Return on Equity: -5.17%
• Return on Assets: -3.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.42
• Quick Ratio: 1.28

Sales & Book Value

• Annual Sales: $832.90 million
• Price / Sales: 0.77
• Cash Flow: $1.04 per share
• Price / Cash Flow: 6.62
• Book Value: $7.70 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 93,045,000
• Free Float: 91,091,000
• Market Cap: $642.94 million
• Optionable: Optionable
• Beta: 1.93